Skip to main content
Erschienen in: International Cancer Conference Journal 3/2019

27.03.2019 | Case report

Primary small cell neuroendocrine carcinoma of adrenal gland

verfasst von: Kosuke Ogawa, Yousuke Shimizu, Shoko Uketa, Noriaki Utsunomiya, Kazutaka Kida, Misa Ishihara, Kimio Hashimoto, Sojun Kanamaru

Erschienen in: International Cancer Conference Journal | Ausgabe 3/2019

Einloggen, um Zugang zu erhalten

Abstract

Neuroendocrine tumors are an extremely rare form of retroperitoneum tumor. A 79-year-old man presented with abdominal pain. Computed tomography and magnetic resonance imaging revealed a 51 × 36 mm mass in the left adrenal gland. Gastrofiberscopy, colonfiberscopy and positron emission tomography were performed and showed no lesions or other malignancies. Endocrine tests were normal. Two months later, the mass had grown to 68 × 52 mm. Suspecting a malignant tumor, we performed laparoscopic adrenalectomy. Histopathological diagnosis revealed the tumor was small cell neuroendocrine carcinoma. No other malignancies were revealed, so we diagnosed primary small cell neuroendocrine carcinoma of adrenal gland. To our knowledge, this is only the third report in English of primary small cell neuroendocrine carcinoma of the adrenal gland and the first report that is confined to the adrenal gland. Adrenal masses are often misdiagnosed as adenoma; however, we need to raise awareness of the potential for malignant adrenal tumors such as the rarer small cell neuroendocrine carcinoma.
Literatur
1.
Zurück zum Zitat Hubalewska-Dydejczyk A, Trofimiuk M, Sowa-Staszczak A et al (2010) Neuroendocrine tumours of rare location. Endokrynol Pol 61:322–327PubMed Hubalewska-Dydejczyk A, Trofimiuk M, Sowa-Staszczak A et al (2010) Neuroendocrine tumours of rare location. Endokrynol Pol 61:322–327PubMed
2.
Zurück zum Zitat Hainsworth JD, Johnson DH, Greco FA (1988) Poorly differentiated neuroendocrine carcinoma of unknown primary site. A newly recognized clinicopathologic entity. Ann Intern Med 109:364–371CrossRefPubMed Hainsworth JD, Johnson DH, Greco FA (1988) Poorly differentiated neuroendocrine carcinoma of unknown primary site. A newly recognized clinicopathologic entity. Ann Intern Med 109:364–371CrossRefPubMed
4.
Zurück zum Zitat Dong A, Zuo C, Wang Y (2013) FDG PET/CT imaging of extrapulmonary small cell carcinoma of the adrenal gland. Clin Nucl Med 38:407–410CrossRef Dong A, Zuo C, Wang Y (2013) FDG PET/CT imaging of extrapulmonary small cell carcinoma of the adrenal gland. Clin Nucl Med 38:407–410CrossRef
5.
Zurück zum Zitat Herrera MF, Grant CS, van Heerden JA et al (1991) Incidentally discovered adrenal tumors: an institutional perspective. Surgery 110:1014–1021PubMed Herrera MF, Grant CS, van Heerden JA et al (1991) Incidentally discovered adrenal tumors: an institutional perspective. Surgery 110:1014–1021PubMed
6.
Zurück zum Zitat Mantero F, Terzolo M, Arnaldi G et al (2000) A survey on adrenal incidentaloma in Italy. Study Group on Adrenal Tumors of the Italian Society of Endocrinology. J Clin Endocrinol Metab 85:637–644PubMed Mantero F, Terzolo M, Arnaldi G et al (2000) A survey on adrenal incidentaloma in Italy. Study Group on Adrenal Tumors of the Italian Society of Endocrinology. J Clin Endocrinol Metab 85:637–644PubMed
7.
Zurück zum Zitat Ball MW, Hemal AK, Allaf ME (2017) International consultation on urological diseases and European association of urology international consultation on minimally invasive surgery in urology: laparoscopic and robotic adrenalectomy. BJU Int 119:13–21CrossRefPubMed Ball MW, Hemal AK, Allaf ME (2017) International consultation on urological diseases and European association of urology international consultation on minimally invasive surgery in urology: laparoscopic and robotic adrenalectomy. BJU Int 119:13–21CrossRefPubMed
8.
Zurück zum Zitat Gonzalez RJ, Shapiro S, Sarlis N et al (2005) Laparoscopic resection of adrenalcortical carcinoma: a cautionary note. Surgery 138:1078–1086CrossRefPubMed Gonzalez RJ, Shapiro S, Sarlis N et al (2005) Laparoscopic resection of adrenalcortical carcinoma: a cautionary note. Surgery 138:1078–1086CrossRefPubMed
9.
Zurück zum Zitat Leboulleux S, Deandreis D, Al Ghuzlan A et al (2010) Adrenocortical carcinoma: is the surgical approach a risk factor of peritoneal carcinomatosis? Eur J Endocrinol 162:1147–1153CrossRefPubMed Leboulleux S, Deandreis D, Al Ghuzlan A et al (2010) Adrenocortical carcinoma: is the surgical approach a risk factor of peritoneal carcinomatosis? Eur J Endocrinol 162:1147–1153CrossRefPubMed
10.
Zurück zum Zitat Lombardi CP, Raffaelli M, De Crea C et al (2006) Role of laparoscopy in the management of adrenal malignancies. J Surg Oncol 94:128–131CrossRefPubMed Lombardi CP, Raffaelli M, De Crea C et al (2006) Role of laparoscopy in the management of adrenal malignancies. J Surg Oncol 94:128–131CrossRefPubMed
11.
Zurück zum Zitat Miller BS, Gauger PG, Hammer GD et al (2012) Resection of adrenocortical carcinoma is less complete and local recurrence occurs sooner and more often after laparoscopic adrenalectomy than after open adrenalectomy. Surgery 152:1150–1157CrossRefPubMed Miller BS, Gauger PG, Hammer GD et al (2012) Resection of adrenocortical carcinoma is less complete and local recurrence occurs sooner and more often after laparoscopic adrenalectomy than after open adrenalectomy. Surgery 152:1150–1157CrossRefPubMed
12.
Zurück zum Zitat Porpiglia F, Fiori C, Daffara F et al (2010) Retrospective evaluation of the outcome of open versus laparoscopic adrenalectomy for stage I and II adrenocortical cancer. Eur Urol 57:873–878CrossRefPubMed Porpiglia F, Fiori C, Daffara F et al (2010) Retrospective evaluation of the outcome of open versus laparoscopic adrenalectomy for stage I and II adrenocortical cancer. Eur Urol 57:873–878CrossRefPubMed
13.
Zurück zum Zitat Chong S, Lee KS, Kim HY et al (2006) Integrated PET-CT for the characterization of adrenal gland lesions in cancer patients: diagnostic efficacy and interpretation pitfalls. Radiographics 26:1811–1824CrossRefPubMed Chong S, Lee KS, Kim HY et al (2006) Integrated PET-CT for the characterization of adrenal gland lesions in cancer patients: diagnostic efficacy and interpretation pitfalls. Radiographics 26:1811–1824CrossRefPubMed
14.
Zurück zum Zitat Shepherd FA, Evans WK, Feld R et al (1988) Adjuvant chemotherapy following surgical resection for small-cell carcinoma of the lung. J Clin Oncol 6:832–838CrossRefPubMed Shepherd FA, Evans WK, Feld R et al (1988) Adjuvant chemotherapy following surgical resection for small-cell carcinoma of the lung. J Clin Oncol 6:832–838CrossRefPubMed
15.
Zurück zum Zitat Lucchi M, Mussi A, Chella A et al (1997) Surgery in the management of small cell lung cancer. Eur J Cardiothorac Surg 12:689–693CrossRefPubMed Lucchi M, Mussi A, Chella A et al (1997) Surgery in the management of small cell lung cancer. Eur J Cardiothorac Surg 12:689–693CrossRefPubMed
16.
Zurück zum Zitat Baka S, Califano R, Ferraldeschi R et al (2008) Phase III randomised trial of doxorubicin-based chemotherapy compared with platinum-based chemotherapy in small-cell lung cancer. Br J Cancer 99:442–447CrossRefPubMedPubMedCentral Baka S, Califano R, Ferraldeschi R et al (2008) Phase III randomised trial of doxorubicin-based chemotherapy compared with platinum-based chemotherapy in small-cell lung cancer. Br J Cancer 99:442–447CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Pujol JL, Carestia L, Daurès JP (2000) Is there a case for cisplatin in the treatment of small-cell lung cancer? A meta-analysis of randomized trials of a cisplatin-containing regimen versus a regimen without this alkylating agent. Br J Cancer 83:8–15CrossRefPubMedPubMedCentral Pujol JL, Carestia L, Daurès JP (2000) Is there a case for cisplatin in the treatment of small-cell lung cancer? A meta-analysis of randomized trials of a cisplatin-containing regimen versus a regimen without this alkylating agent. Br J Cancer 83:8–15CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Hill JS, McPhee JT, McDade TP et al (2009) Pancreatic neuroendocrine tumors: the impact of surgical resection on survival. Cancer 115:741–751CrossRefPubMed Hill JS, McPhee JT, McDade TP et al (2009) Pancreatic neuroendocrine tumors: the impact of surgical resection on survival. Cancer 115:741–751CrossRefPubMed
19.
Zurück zum Zitat Clark OH, Benson AB 3rd, Berlin JD et al (2009) NCCN clinical practice guidelines in oncology: neuroendocrine tumors. J Natl Compr Cancer Netw 7:712–747CrossRef Clark OH, Benson AB 3rd, Berlin JD et al (2009) NCCN clinical practice guidelines in oncology: neuroendocrine tumors. J Natl Compr Cancer Netw 7:712–747CrossRef
20.
Zurück zum Zitat Fjällskog ML1, Granberg DP, Welin SL et al (2001) Treatment with cisplatin and etoposide in patients with neuroendocrine tumors. Cancer 92:1101–1107CrossRefPubMed Fjällskog ML1, Granberg DP, Welin SL et al (2001) Treatment with cisplatin and etoposide in patients with neuroendocrine tumors. Cancer 92:1101–1107CrossRefPubMed
Metadaten
Titel
Primary small cell neuroendocrine carcinoma of adrenal gland
verfasst von
Kosuke Ogawa
Yousuke Shimizu
Shoko Uketa
Noriaki Utsunomiya
Kazutaka Kida
Misa Ishihara
Kimio Hashimoto
Sojun Kanamaru
Publikationsdatum
27.03.2019
Verlag
Springer Singapore
Erschienen in
International Cancer Conference Journal / Ausgabe 3/2019
Elektronische ISSN: 2192-3183
DOI
https://doi.org/10.1007/s13691-019-00368-4

Weitere Artikel der Ausgabe 3/2019

International Cancer Conference Journal 3/2019 Zur Ausgabe

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

27.05.2024 Blut im Stuhl Nachrichten

Immunchemischer Stuhltest positiv, Koloskopie negativ – in solchen Fällen kann die Blutungsquelle auch weiter proximal sitzen. Ein Forschungsteam hat nachgesehen, wie häufig und in welchen Lokalisationen das der Fall ist.

Mammakarzinom: Brustdichte beeinflusst rezidivfreies Überleben

26.05.2024 Mammakarzinom Nachrichten

Frauen, die zum Zeitpunkt der Brustkrebsdiagnose eine hohe mammografische Brustdichte aufweisen, haben ein erhöhtes Risiko für ein baldiges Rezidiv, legen neue Daten nahe.

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.